Jenkins Annalisa 4

What Happened
Annalisa Jenkins, a director of Skye Bioscience, was granted a derivative award for 35,000 shares on 2026-02-06. The Form 4 reports the acquisition as a grant/award (code A) with a reported price of $0.00 — this reflects a stock option award rather than a cash purchase or sale. The filing shows the award vests in equal monthly installments over the one-year period beginning January 19, 2026.

Key Details

• Transaction date: 2026-02-06; Form 4 filed: 2026-02-09 (filed within the SEC two-business-day window).
• Transaction type/code: Award/Grant (A); reported amount: 35,000 shares; price reported: $0.00 (derivative).
• Vesting: Options vest in equal monthly installments over one year starting Jan 19, 2026 (footnote).
• Shares owned after transaction: Not specified in the filing.
• This is a grant of derivative securities (stock options), not an open-market purchase or sale.

Context
A grant/award (derivative) typically means the insider received options or similar rights that convert to or allow purchase of common shares over time; it does not represent an immediate sale or cash proceeds. For retail investors, grants signal compensation or retention incentives but are not direct indications of the insider buying or selling stock.